Neue Antibiotika bei schwerer Sepsis - der Durchbruch?

Literatur

• 1 Bodi M, Ardanuy C, Olona M. et al . Therapy for ventilator-associated pneumonia: the Tarragona strategy.  Clin Microbiol Infect. 2001;  7 32-33
  Google Scholar
• 2 Bochud P Y, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock.  Crit Care Med. 2004;  32 S495-512
  Google Scholar
• 3 Dellinger R P, Levy M M, Carlet J M. et al . Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008.  Crit Care Med. 2008;  36 296-327
  Google Scholar
• 4 Gomez J, Garcia-Vazquez E, Banos R. et al . Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia.  Eur J Clin Microbiol Infect Dis. 2007;  26 239-245
  Google Scholar
• 5 Kumar A, Roberts D, Wood K E. et al . Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.  Crit Care Med. 2006;  34 1589-1596
  Google Scholar
• 6 Lentino J R, Narita M, Yu V L. New antimicrobial agents as therapy for resistant gram-positive cocci.  Eur J Clin Microbiol Infect Dis. 2008;  27 3-15
  Google Scholar
• 7 Pea F, Viale P. The antimicrobial therapy puzzle.  Clin Infect Dis. 2006;  42 1764-1771
  Google Scholar
• 8 Valles J, Rello J, Ochagavia A, Garnacho J, Alcala M A. Community-acquired bloodstream infection in critically ill adult patients.  Chest. 2003;  123 1615-1624
  Google Scholar

Univ. Prof. Dr. Heinz Burgmann

Innere Medizin I, Klinische Abteilung für Infektionen und Tropenmedizin, Medizinische Universität Wien

Währinger Gürtel 18 - 20

A-1090 Wien

Phone: 0043 1 40400 4440

Fax: 0043 1 40400 4440

Email: heinz.burgmann@meduniwien.ac.at